Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0012739 (
disseminated intravascular coagulation
)
8,673
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The aim of our study was to evaluate the impact of oral arsenic (the realgar-indigo naturalis formula,
RIF
) and all-trans retinoic acid (ATRA) on coagulopathy in acute promyelocytic leukemia (APL) compared with intravenous arsenic trioxide (ATO) and ATRA during induction. Mitoxantrone was added to all the patients at a dose of 1.4mg/m
2
per day for 5-7 days. D-dimer levels, prothrombin time (PT), fibrinogen (Fbg) levels and the platelet count were comparably analyzed among 83 newly diagnosed APL patients treated with
RIF
(n=45) or with ATO (n=38). Since induction therapy with
RIF
and ATRA, the median levels of Fbg, PT and platelets were recovered to the normal range within 4days, 10days and 28days, respectively. The last day of platelet and plasma transfusion was day 12 (range: 0-24 days) and day 3 (range: 0-27 days), respectively. Among the 42 patients with a
disseminated intravascular coagulation
(
DIC
) score=4, the consumption of transfused platelets was less in the
RIF
group than that in the ATO group (P=0.037). In the 17 patients with a
DIC
score <4, prompt recovery of Fbg levels (P=0.028) was observed in the
RIF
group compared with that in the ATO group (P=0.401).
RIF
and ATO showed similar effects on the recovery of coagulopathy in APL patients.
RIF
had a potential beneficial effect in accelerating the recovery of thrombocytopenia and hypofibrinogenemia for subclinical
DIC
patients.
...
PMID:The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia. 2923 92
